Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Metadata
Title
The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors
Author
Kamran Ahrar, MD
Publication date
01-08-2004
Publisher
Current Medicine Group
Published in
Current Oncology Reports / Issue 4/2004
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-004-0042-1

Other articles of this Issue 4/2004

Current Oncology Reports 4/2004 Go to the issue

Editor’s Commentary

Translating the results of phase III randomized cancer trials into the language of physician obligation to patients

OriginalPaper

Role of gene expression arrays in sarcomas

Abstract

Literature alert

BriefCommunication

Clinical Trials Report

OriginalPaper

Adjuvant therapy for resected non-small-cell lung cancer: Recent advances, emerging agents, and lingering questions

OriginalPaper

Treatment options for small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits